News
-
-
-
-
-
PRESS RELEASE
Phase III GRAPPA trial supports ATLG (Grafalon®) as standard of care in matched unrelated donor stem cell transplantation
Phase III GRAPPA trial results show ATLG (Grafalon®) superiority in unrelated donor stem cell transplantation. Lower mortality and infection rates support its continued use as standard care -
-
-
-
-